---
title: "Stocks in Play:  Satellos Bioscience Inc."
description: "10:21 AM EST - Satellos Bioscience Inc. : Today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275777320.md"
published_at: "2026-02-12T15:22:17.000Z"
---

# Stocks in Play:  Satellos Bioscience Inc.

> 10:21 AM EST - Satellos Bioscience Inc. : Today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy. Satellos Bioscience Inc. shares T.MSCL are trading up $0.43 at $16.20.

**10:21 AM EST - Satellos Bioscience Inc. :** Today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy. Satellos Bioscience Inc. shares T.MSCL are trading **up $0.43** at $16.20.

### Related Stocks

- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [ASMB.US - Assembly Biosciences](https://longbridge.com/en/quote/ASMB.US.md)
- [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md)
- [TBIO.US - Telesis Bio](https://longbridge.com/en/quote/TBIO.US.md)
- [MSLE.US - Satellos Bioscience](https://longbridge.com/en/quote/MSLE.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| AI 制药企业 Generate BiomedicinesIPO 定价 16 美元/股 今晚登陆纳斯达克 | AI 药物研发公司 Generate Biomedicines 正式公布 IPO 发行价为每股 16 美元，计划今晚在纳斯达克上市，发行 2500 万股，募资 4 亿美元。该公司专注于免疫学与肿瘤学，利用人工智能技术开发药物，三款蛋白质药物 | [Link](https://longbridge.com/en/news/277153682.md) |
| 新冠疫苗制造商诺瓦瓦克斯因销售额攀升而扭亏为盈 | 诺瓦瓦克斯公司（纳斯达克股票代码：NVAX）因销售额攀升而扭亏为盈，第四季度每股收益为 11 美分，营收为 1.47 亿美元，同比增长 67%。公司超额完成 2025 年成本削减目标，并预计 2026 年研发与销售及管理费用为 3.25 亿 | [Link](https://longbridge.com/en/news/277089687.md) |
| 围攻侏儒症 “药王” | 侏儒症的治疗正迎来变革。BioMarin 的 Vosoritide 是首个获批药物，预计 2025 年销售额达 9.27 亿美元，但多款新药正在挑战其市场地位。Ascendis 的 TransCon-CNP 和 BridgeBio 的 In | [Link](https://longbridge.com/en/news/277272274.md) |
| 中邮证券：siRNA 药物机制优势突出 递送为核心技术 | 中邮证券发布研报指出，siRNA 药物在精准沉默致病蛋白方面具有显著优势，递送系统是核心技术。与传统小分子和生物药相比，siRNA 药物的核酸疗法已成为新药开发的热门方向。海外企业如 Alnylam、Arrowhead 等已进入临床后期，国 | [Link](https://longbridge.com/en/news/277137610.md) |
| 百济神州首次盈利背后的喜与忧 | 百济神州在 2025 年首次实现全年盈利，调整后净利润达 9.18 亿美元，营业总收入 53.43 亿美元，同比增长 40.23%。尽管核心产品百悦泽推动了业绩增长，第四季度经调整毛利率提升至 90.69%，但环比数据表现平平，费用显著上升 | [Link](https://longbridge.com/en/news/277187099.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.